RDS2026 合作伙伴｜PSI CRO：全球临床 CRO，专注放射性药物临床研究

放射性药物，亦称核药，核药作为核技术在医疗领域的典型应用，正处于全球精准医疗产业革新的前沿。这类药物凭借其独特的“诊疗一体化”特性，将放射性核素与配体相结合，既能在早期精准定位病灶，又能直接靶向作用于细胞，极大地提升了治疗效果，同时降低了系统性副作用，在肿瘤、神经退行性疾病等重大病症的诊治中展现出无可比拟的价值，已然成为全球药企与资本激烈角逐的新高地。

监管路径、医用同位素供应、新靶点、新核素、新配体等热点问题持续受到关注，因此我们再度聚焦核药，将于2026年3月19-20日在上海浦东滨江喜来登酒店召开第三届全球核药开发峰会，为产学研医搭建良好的沟通桥梁，致力于进一步提升我国核药研发能力和创新水平，推动产业迈向高质量发展的新阶段。

PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2025.

The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.

In 2025, PSI celebrated its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,200 people across 58 countries as of December 31st, 2025.

Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.

For more information, visit www.psi-cro.com.”

Jason Vilardi, CNMT, RT(N)(ARRT) is a clinical imaging and development expert with over 15 years of experience advancing radio-pharm, oncology, hematology, and cell therapy trials. He has led the creation and optimization of imaging operations, built specialized teams, and driven innovation in trial delivery across global programs. Jason’s strengths include protocol development, regulatory strategy, imaging biomarker integration, and audit readiness. His ability to translate complex clinical strategies into actionable study designs has made him a trusted partner in cross-functional leadership and scientific execution.

He has implemented predictive analytics infrastructure, streamlined case assignment processes, and served as the primary contact for numerous global audits. Jason maintains strong relationships with key experts and study sites, contributing to protocol design, training, and data interpretation. His work continues to shape the future of clinical imaging through strategic insight, operational excellence, and scientific rigor.